High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers
Liver International · 2025
DOI: 10.1111/liv.70255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Elsie Ennin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors, Liver Neoplasms, Sorafenib. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Background & Aims Immune checkpoint inhibitors (ICIs) are therapy for many malignancies including hepatocellular carcinoma (HCC), yet the impact of HCC on immune‐mediated liver injury from checkpoint inhibitors (ILICI) remains poorly understood and no direct comparison exists for hepatotoxicity rates between ICI and sorafenib in HCC.
Methods
In this retrospective cohort study, we extracted data on adult patients treated with five ICI regimens for HCC or non‐HCC cancers, and HCC patients who received sorafenib between 2010 and 2020. The primary outcome was grade ≥ 3 ILICI or sorafenib (DILI). Logistic regression estimated adjusted odds ratios (OR) for liver injury.
Results
We identified 530 patients, 129 (24%) HCC‐ICI, 256 (48%) non‐HCC ICI, and 145 (27%) HCC‐sorafenib. Compared to non‐HCC ICI, HCC‐ICI and HCC‐sorafenib were more often male (57%, 82%, 77%), Hispanic (14%, 35%, 34%), and cirrhotic (1%, 85%, 88%). Twenty‐three patients developed grade ≥ 3 ILICI. ILICI incidence was higher for HCC‐ICI (11%, CI 6–18) versus non‐HCC ICI (4%, CI 2–6, p = 0.006) and DILI in HCC‐sorafenib (3%, CI 1–8, p = 0.02) with incidence highest for ipilimumab‐nivolumab (HCC‐ICI 42%, CI 15–72 versus non‐HCC 10%, CI 3–24; p = 0.02). On multivariable regression, ILICI was associated with HCC (OR 4.5, CI 1.8–11.4, p = 0.002) and treatment with ipilimumab‐nivolumab (OR 6.9, CI 2.6–18.3, p < 0.001). Incidence of liver injury in HCC remained elevated for ICI versus sorafenib (OR 3.5, CI 1.2–10.4, p = 0.02).
Conclusions
We identified an elevated risk of liver injury in HCC patients receiving ICIs compared to ICI‐treated non‐HCC cancers and sorafenib‐treated HCC, with dual ipilimumab‐nivolumab therapy carrying the highest risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
- Department of Medicine, Huntington Health, Pasadena, California, USA.
- Division of Gastrointestinal and Liver Diseases, Research Center for Liver Disease, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Division of Hematology and Oncology, Norris Comprehensive Cancer Center, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
ORCID-Profile: Elsie Ennin, Kali Zhou, Jeffrey Kahn
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Ennin, E., Mallepally, N., Ali, M., Shojaie, L., Dewberry, S., Trieu, M., Torres, E. T. R., Zhou, K., Kahn, J., Dodge, J. L., & Dara, L. (2025). High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers. Liver International. https://doi.org/10.1111/liv.70255
Vancouver
Ennin E, Mallepally N, Ali M, Shojaie L, Dewberry S, Trieu M, et al. High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers. Liver International. 2025. doi:10.1111/liv.70255
BibTeX
@article{Ennin2025,
author = {Ennin, Elsie and Mallepally, Niharika and Ali, Myra and Shojaie, Layla and Dewberry, Sean and Trieu, Melissa and Torres, Evanthia T Roussos and Zhou, Kali and Kahn, Jeffrey and Dodge, Jennifer L and Dara, Lily},
title = {High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70255}
}
EUVIMED